Drug Search Results
More Filters [+]

Paclitaxel poliglumex

Alternative Names: paclitaxel poliglumex
Latest Update: 2022-12-10
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: Tubulin Binder

Novel Mechanism: Yes

Modality: Large Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Uruguay

Approved Indications: None

Known Adverse Events: None

Company: CTI BioPharma
Company Location: SEATTLE WA 98121
Company CEO: Adam R. Craig
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Paclitaxel poliglumex

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Non-Small-Cell Lung Cancer|Small Cell Lung Cancer

Phase 2: Peritoneal Cancer|Squamous Cell Carcinoma|Head and Neck Cancer|Ovarian Cancer|Fallopian Tube Cancer|Prostate Cancer|Esophageal Cancer|Non-Small-Cell Lung Cancer

Phase 1: Colorectal Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

X90003

P2

Completed

Squamous Cell Carcinoma|Head and Neck Cancer

2016-12-01

CTI#X64001

P2

Completed

Esophageal Cancer

2010-02-01

2007-004167-22

P3

Active, not recruiting

Non-Small-Cell Lung Cancer

2009-11-23

D-0433

P2

Completed

Non-Small-Cell Lung Cancer

2009-11-01

Recent News Events